Dublin, Dec. 11, 2014 (GLOBE NEWSWIRE) -- Research and Markets ( http://www.researchandmarkets.com/research/k8...obal_fabry ) has announced the addition of the "Global Fabry Disease Market 2015-2019" report to their offering.
Fabry disease is an inheritable lysosomal storage disease characterized by the excessive accumulation of globotriaosylceramide (GL-3) in lysosomes. It results from a deficiency of a-Gal and can result in symptoms such as fatigue, angiokeratoma, tinnitus, kidney failure, heart disorders, and nervous system problems. Fabry disease results from mutations in the galactosidase (GLA) gene, resulting in decreased activity or complete absence of a-Gal.
Fabry disease resulting from the decreased activity of the enzyme is called later-onset Fabry disease. This form of the disease can effect both males and females. The symptoms of this disease typically appear during adulthood and usually focus on a single organ. Fabry disease resulting from the complete absence of a-Gal results in a more severe form called classic Fabry disease. The classic form of the disease usually affects males.
The disease symptoms usually starts in adolescence and include clouded eye lenses, skin lesions, pain, and reduced sweating. If untreated, the disease can lead to cardiac dysfunction, renal failure or stroke, often resulting in death during fourth or fifth decade of life.
The analysts forecast the Global Fabry Disease market to grow at a CAGR of 18.08 percent over the period 2014-2019.
This report covers the present scenario and the growth prospects of the Global Fabry Disease market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various innovator drugs available in the market for the treatment of fabry disease.
The report, the Global Fabry Disease Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Fabry Disease market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
One key trend in the market is an increase in regulatory assistance in emerging nations. Regulatory bodies are steadily working toward developing guidelines and providing assistance to drug manufacturers to promote research in this area.
According to the report, special provisions for orphan drugs are one of the major drivers of this market. Special incentives in the form of funding, guidance, and market exclusivity offer an attractive opportunity to vendors to conduct research in this area.
Key Topics Covered:
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
04. Market Research Methodology
05. Disease Overview
06. Introduction
07. Market Landscape
08. Market Segmentation by Cell Line Used for Manufacturing the Drug
09. Geographical Segmentation
10. Buying Criteria
11. Market Growth Drivers
12. Drivers and their Impact
13. Market Challenges
14. Impact of Drivers and Challenges
15. Market Trends
16. Trends and their Impact
17. Vendor Landscape
18. Pipeline Analysis
19. Fabry Registry
20. Key Vendor Analysis
21. Other Reports in this Series
Companies Mentioned:
- Genzyme
- Shire
- Amicus Therapeutics
- Green Cross Corporation
- ISU Abxis
- JCR Pharmaceuticals
- Protalix Biotherapeutics
For more information visit http://www.researchandmarkets.com/research/k8...obal_fabry
Research and Markets Laura Wood, Senior Manager For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Sector: Healthcare and Medical Devices
